GlassScriptPhysician profile
Ryan Andrew Matthiesen
NPI 1326480732
$2,620.22
in general payments reported to CMS, 2019-2025
26 companies · $55.76 in 2025
The $55.76 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $313 · 2022: $478 · 2023: $452 · 2024: $1,322 · 2025: $55.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215 · Travel and Lodging: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.74 |
| Travel and Lodging | $614.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $887.88 | 2024 | Iovera |
| Abbvie INC. | $362.60 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.76 | 2023-2024 | Lifevest |
| Mannkind Corporation | $153.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.80 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $93.96 | 2021-2024 | Zepbound, Mounjaro |
| Novo Nordisk INC | $89.09 | 2022-2023 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $87.16 | 2021-2022 | |
| Abbott Laboratories | $68.68 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $65.80 | 2021-2025 | |
| Astellas Pharma US INC | $63.53 | 2022-2023 | Veozah |
| Bioventus LLC | $57.24 | 2022-2023 | Durolane |
| Biohaven Pharmaceutical Holding Company LTD. | $53.72 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $49.96 | 2023-2024 | Rexulti |
| Dexcom, INC. | $39.49 | 2024-2025 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $38.99 | 2024 | Xelstrym |
| Sumitomo Pharma America, INC. | $30.16 | 2023 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $28.23 | 2024 | Airsupra, Farxiga |
| Lundbeck LLC | $25.12 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $24.81 | 2024 | Trelegy Ellipta |
| Biogen, INC. | $24.06 | 2024 | Skyclarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.87 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $19.44 | 2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $16.37 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $14.00 | 2024 | Gardasil, Vaxelis, Capvaxive |
| Paratek Pharmaceuticals, INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Matthiesen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.